500 related articles for article (PubMed ID: 29733441)
21. Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and Commonly Used Drugs for Gout Treatment.
Shen Z; Tieu K; Wilson D; Bucci G; Gillen M; Lee C; Kerr B
Clin Pharmacol Drug Dev; 2017 Jul; 6(4):377-387. PubMed ID: 28074640
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
Gupta MK; Singh JA
Drugs; 2019 Apr; 79(5):531-541. PubMed ID: 30868398
[TBL] [Abstract][Full Text] [Related]
23. Guideline development for the management of gout: role of combination therapy with a focus on lesinurad.
Jones G; Panova E; Day R
Drug Des Devel Ther; 2017; 11():3077-3081. PubMed ID: 29123379
[TBL] [Abstract][Full Text] [Related]
24. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
Shiramoto M; Liu S; Shen Z; Yan X; Yamamoto A; Gillen M; Ito Y; Hall J
Rheumatology (Oxford); 2018 Sep; 57(9):1602-1610. PubMed ID: 29868853
[TBL] [Abstract][Full Text] [Related]
25. Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout.
Hill-McManus D; Soto E; Marshall S; Lane S; Hughes D
Br J Clin Pharmacol; 2018 Jan; 84(1):142-152. PubMed ID: 28888218
[TBL] [Abstract][Full Text] [Related]
26. Lesinurad: A Novel Agent for Management of Chronic Gout.
Haber SL; Fente G; Fenton SN; Walker EP; Weaver BM; Cano AJ; Vu K
Ann Pharmacother; 2018 Jul; 52(7):690-696. PubMed ID: 29482353
[TBL] [Abstract][Full Text] [Related]
27. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study.
Dalbeth N; Jones G; Terkeltaub R; Khanna D; Fung M; Baumgartner S; Perez-Ruiz F
Arthritis Res Ther; 2019 Jan; 21(1):8. PubMed ID: 30616614
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout.
Kankam M; Hall J; Gillen M; Yang X; Shen Z; Lee C; Liu S; Miner JN; Walker S; Clauson V; Wilson D; Nguyen M
J Clin Pharmacol; 2018 Sep; 58(9):1214-1222. PubMed ID: 29733447
[TBL] [Abstract][Full Text] [Related]
30. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
31. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
Miner JN; Tan PK; Hyndman D; Liu S; Iverson C; Nanavati P; Hagerty DT; Manhard K; Shen Z; Girardet JL; Yeh LT; Terkeltaub R; Quart B
Arthritis Res Ther; 2016 Oct; 18(1):214. PubMed ID: 27716403
[TBL] [Abstract][Full Text] [Related]
32. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
Cutolo M; Cimmino MA; Perez-Ruiz F
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
[TBL] [Abstract][Full Text] [Related]
33. Budget impact of adding lesinurad for second-line treatment of gout: a US health plan perspective.
Klein RW; Kabadi S; Cinfio FN; Bly CA; Taylor DC; Szymanski KA
J Comp Eff Res; 2018 Aug; 7(8):807-816. PubMed ID: 29792516
[No Abstract] [Full Text] [Related]
34. Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout.
Terkeltaub R; Saag KG; Goldfarb DS; Baumgartner S; Schechter BM; Valiyil R; Jalal D; Pillinger M; White WB
Rheumatology (Oxford); 2019 Jan; 58(1):61-69. PubMed ID: 30124941
[TBL] [Abstract][Full Text] [Related]
35. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
[TBL] [Abstract][Full Text] [Related]
36. Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamics.
Aksenov S; Peck CC; Eriksson UG; Stanski DR
Physiol Rep; 2018 Mar; 6(5):. PubMed ID: 29488355
[TBL] [Abstract][Full Text] [Related]
37. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout.
Pérez-Ruiz F; Jansen T; Tausche AK; Juárez-Campo M; Gurunath RK; Richette P
Drugs Context; 2019; 8():212581. PubMed ID: 31191704
[TBL] [Abstract][Full Text] [Related]
39. Comparative efficacy and safety of lesinurad 200 mg and 400 mg combined with a xanthine oxidase inhibitor in hyperuricemic patients with gout: A Bayesian network meta-analysis of randomized controlled trials
.
Song GG; Lee YH
Int J Clin Pharmacol Ther; 2019 Jul; 57(7):345-352. PubMed ID: 30990408
[TBL] [Abstract][Full Text] [Related]
40. Lesinurad: First Global Approval.
Hoy SM
Drugs; 2016 Mar; 76(4):509-16. PubMed ID: 26861027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
